09:00-10:30
PSMA therapy: Is the magic filter of eternity?
Chairpersons : Mariela Agolti, NN
09:00-09:20 Dimitrios Vomvas The Prelude to Precision: Therapeutic Strategies Before PSMA
09:20-09:40 Andrei Iagaru, Patient selection for RLT (Lu177 PSMA) and assessment of response
09:40-10:00 Akram El-Ibraheem Highlights and pitfalls of starting a PSMA theragnostics service
10:00- 10:20 Mike Sathekge, Tc-99m/Re-188 PSMA in Prostate Cancer.
10:20- 10:30 Discusion
10:30-11:00 Coffee Break
11:00-13:00 Session 3
Peptide receptor radionuclide therapy: The domestication of zebra
Chairpersons: Ioannis Karfis NN
11:00-11:20 Pantelis Kountourakis Is PRRT Making a Difference in Patient Management?
11.20-11.40 Irene Virgolini PRRT; how to we move forwards?
11:40-12:00 Gopinath Gnansegaran PRRT: Management of High risk patients and side effects
12:00-12:20 Masha Maharaj The Power of Sequence: Enhancing Outcomes in Neuroendocrine Tumors.
12:20-12:40 Josh Mailman “Where can I get PRRT” The role of patient advocacy in developing new theragnostic centres
12:40-13:00 Satoshi Minoshima , USA Neurological Theragnostics
13:00-13:30 Industry Symposium
13:30-14:30 Lunch and poster walk
14:30-16:00 Session 4 Road to Cartagena
Thyroid Cancer Therapy: The Foundations of Nuclear Medicine
Chairpersons: Savvas Frangos, Siroos Mirzaei
14:30-14:50 John Buscombe Simply the best; Why after 80 years I-131 is still king
14:50-15:10 Isabel Melero EANM guideline for radioiodine treatment in patients on hemodialysis.
15:10-15:30 Michael Kreissl Radioiodine refractory thyroid cancer: the role of new targets and theranostics
15:30-15:50 Haris Haralampous MKI s and the difficulties managing the side effects
15:50- 16:00 Discusion
16:00-16:30 Coffee Break
16:30-18:00 Session 5
FRT- FAP Directed Radiopharmaceutical Therapy: Is the future here?
Chairpersons: Raluca Mititelu, Diogenis Kyprianou
16:30-16:50 Partha Choudhury FAPI in gastric and lung cancer
16:50-17:10 Akram Al-Ibraheem Navigating Challenges in interpretation of FAPI PET/CT
17:10-1750 Richard Baum FAP-Targeted Radiopharmaceutical Therapy in More Than 20 Cancer Types: Insights from Six Years of Clinical Experience and Future Directions
17:50-18:00 Discussion